165 related articles for article (PubMed ID: 38141113)
1. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Dos Santos MV; Holth A; Bischof K; Davidson B
Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
[TBL] [Abstract][Full Text] [Related]
2. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
3. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
Davidson B; Doutel D; Holth A; Nymoen DA
Virchows Arch; 2023 Jun; 482(6):975-982. PubMed ID: 37067588
[TBL] [Abstract][Full Text] [Related]
4. Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
[TBL] [Abstract][Full Text] [Related]
5. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2021 Mar; 32(2):161-168. PubMed ID: 33025675
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
Dos Santos MV; Holth A; Lindemann K; Staff AC; Davidson B
Gynecol Oncol; 2023 Sep; 176():76-81. PubMed ID: 37478615
[TBL] [Abstract][Full Text] [Related]
7. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract][Full Text] [Related]
8. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
[TBL] [Abstract][Full Text] [Related]
9. Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma.
Chehover M; Reich R; Davidson B
Virchows Arch; 2020 Aug; 477(2):249-258. PubMed ID: 31900634
[TBL] [Abstract][Full Text] [Related]
10. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Davidson B
Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
[TBL] [Abstract][Full Text] [Related]
11. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
12. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
13. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
Davidson B; Elstrand MB
Cytopathology; 2022 Jul; 33(4):479-492. PubMed ID: 35398934
[TBL] [Abstract][Full Text] [Related]
15. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; Holth A; Dong HP
Virchows Arch; 2020 Nov; 477(5):677-685. PubMed ID: 32472195
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.
Brunetti M; Holth A; Panagopoulos I; Staff AC; Micci F; Davidson B
Virchows Arch; 2019 Feb; 474(2):177-185. PubMed ID: 30467600
[TBL] [Abstract][Full Text] [Related]
17. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
18. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
19. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
20. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]